Platelet Inhibitors: What are the Risks?;Thrombozytenaggregationshemmer: Was sind die Risiken?

Praxis

Volumn 102, Issue 20, 2013, Pages 1243-1250

  Curkovic, Ivanka ^a   Egbring, Marco ^a   Kullak Ublick, Gerd A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adverse drug events; Bleeding risk; Platelet inhibitors; Prasugrel; Ticagrelor

Indexed keywords

CLOPIDOGREL; PRASUGREL; TICAGRELOR; ACETYLSALICYLIC ACID; ADENOSINE; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

ADVERSE OUTCOME; AGE; ARTICLE; BODY WEIGHT; DRUG SAFETY; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; HUMAN; ISCHEMIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; BLEEDING; BLOOD; CHEMICALLY INDUCED; CORONARY DISEASE; DRUG COMBINATION; DRUG INTERACTION; DRUG RESISTANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADENOSINE; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; CORONARY DISEASE; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STENTS; THIOPHENES; TICLOPIDINE;

EID: 84886899772     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/1661-8157/a001431     Document Type: Article

References (50)

1. Hamm CW, Bassand JP, Agewall S, et al.: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes ( ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology ( ESC). Eur Heart J 2011; 32: 2999-3054.
2. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
3. Berger JS, Brown DL, Becker RC: Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008; 121: 43-49.
4. Bartolucci AA, Tendera M, Howard G: Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011; 107: 1796-1801
5. Yeomans ND, Lanas AI, Talley NJ, et al.: Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795-801.
6. Weil J, Colin-Jones D, Langman M, et al.: Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-830.
7. Lanas A, Wu P, Medin J, Mills EJ: Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol 2011; 9: 762-768 e6.
8. Mehta SR, Bassand JP, Chrolavicius S, et al.: Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930-942.
9. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV: Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
10. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR: Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195-198.
11. Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA: Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation 2013; 127: 377-385.
12. Tantry US, Bliden KP, Gurbel PA: Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46: 1705-1709.
13. Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N: The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 2008; 101: 1060-1063.
14. Schuijt MP, Huntjens-Fleuren HW, de Metz M, Vollaard EJ: The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. Br J Pharmacol 2009; 157: 931-934.
15. Bhatt DL, Scheiman J, Abraham NS, et al.: ACCF/ ACG/ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52: 1502-1517.
16. Bhatt DL: NSAIDS and the risk of myocardial infarction: do they help or harm? Eur Heart J 2006; 27: 1635-1636.
17. Meek IL, Vonkeman HE, Kasemier J, Movig KL, van de Laar MA: Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol 2012; 69: 365-371.
18. Mehta SR, Yusuf S, Peters RJ, et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI- CURE study. Lancet 2001; 358: 527-533.
19. Yusuf S, Zhao F, Mehta SR, et al.:: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
20. Steinhubl SR, Berger PB, Mann JT, 3rd, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420.
21. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events ( CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
22. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV: Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-231.
23. Mega JL, Simon T, Collet JP, et al.: Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304: 1821-1830.
24. Shuldiner AR, O'Connell JR, Bliden KP, et al.: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857.
25. Mega JL, Hochholzer W, Frelinger AL 3rd, et al.: Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011; 306: 2221-2228.
26. Collet JP, Hulot JS, Anzaha G, et al.: High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv 2011; 4: 392-402.
27. Price MJ, Berger PB, Teirstein PS, et al.: Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305: 1097-1105.
28. Gilard M, Arnaud B, Cornily JC, et al.: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
29. O'Donoghue ML, Braunwald E, Antman EM, et al.: Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997.
30. Neubauer H, Engelhardt A, Kruger JC, et al.: Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol 2010; 56: 91-97.
31. Angiolillo DJ, Gibson CM, Cheng S, et al.: Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebocontrolled, crossover comparison studies. Clin Pharmacol Ther 2011; 89: 65-74.
32. Kwok CS, Loke YK: Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010; 31: 810-823.
33. Siller-Matula JM, Jilma B, Schrör K, Christ G, Huber K: Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010; 8: 2624-2641.
34. Lima JP, Brophy JM: The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Med 2010; 8: 81.
35. Mega JL, Close SL, Wiviott SD, et al.: Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON- TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-1319.
36. Wiviott SD, Braunwald E, McCabe CH, et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
37. Wallentin L, Becker RC, Budaj A, et al.: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
38. Wallentin L, James S, Storey RF, et al.: Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
39. Storey RF, Bliden KP, Patil SB, et al.: Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/ OFFSET study. J Am Coll Cardiol 2010; 56: 185-193.
40. Gaglia MA, Jr., Waksman R: Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor. Circulation 2011; 123: 451-456.
41. Bhatt DL, Lincoff AM, Gibson CM, et al.: Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-2341.
42. Harrington RA, Stone GW, McNulty S, et al.: Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-2329.
43. Bhatt DL, Stone GW, Mahaffey KW, et al.: Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. N Engl J Med 2013; 368:1303-1313.
44. Angiolillo DJ, Firstenberg MS, Price MJ, et al.: Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307: 265-274.
45. Welsh RC, Rao SV, Zeymer U, et al.: A randomized, double-blind, active- controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE- PCI trial. Circ Cardiovasc Interv 2012; 5: 336-346.
46. Morrow DA, Braunwald E, Bonaca MP, et al.: Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-1413.
47. Tricoci P, Huang Z, Held C, et al.: Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20-33.
48. Lee M, Saver JL, Hong KS, Wu HC, Ovbiagele B: Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists. Stroke 2012; 43: 3189-3195.
49. Bousser MG, Amarenco P, Chamorro A, et al.: Terutroban versus aspirin in patients with cerebral ischaemic events ( PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011; 377: 2013-2022.
50. Ungerer M, Rosport K, Bültmann A, et al.: Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011; 123: 1891-1899.